Primary Myelofibrosis Pipeline Analysis Report 2026

Primary myelofibrosis is a rare, chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, and progressive cytopenias. The disease has an estimated prevalence of approximately 1-5 cases per 100,000 people globally, primarily affecting older adults. Despite its low prevalence, significant unmet clinical needs persist due to anemia and disease progression. According to the analyst, the primary myelofibrosis pipeline analysis highlights expanding innovation beyond JAK inhibition, with emerging targeted and disease-modifying therapies reshaping the competitive landscape.

Report Coverage

The Primary Myelofibrosis Pipeline Analysis Report gives comprehensive insights into primary myelofibrosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for primary myelofibrosis. The primary myelofibrosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The primary myelofibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with primary myelofibrosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to primary myelofibrosis.

Primary Myelofibrosis Pipeline Outlook

The primary myelofibrosis pipeline outlook highlights continued innovation aimed at overcoming limitations of current standards of care.

Primary myelofibrosis treatment typically centers on JAK inhibitors such as ruxolitinib and fedratinib to reduce splenomegaly and symptom burden, though disease progression and cytopenias remain significant challenges. Reflecting regulatory momentum, in June 2025, the U.S. Food and Drug Administration granted Fast Track designation to nuvisertib (TP-3654), an investigational oral PIM1 kinase inhibitor, for intermediate- or high-risk myelofibrosis. This designation supports accelerated development and underscores growing interest in targeted, non-JAK pathway approaches within the evolving myelofibrosis therapeutic landscape.

Primary Myelofibrosis Epidemiology

Primary myelofibrosis is a rare myeloproliferative neoplasm most commonly diagnosed in adults over 50 years of age, with a median age of about 65 years at diagnosis. The disorder affects males and females equally. In the United States, the incidence is around 1.5 cases per 100,000 people annually, while studies in Northern Europe report about 0.5 per 100,000 per year, though worldwide incidence is not well defined. Although the condition may occur at any age, but pediatric cases are rare and typically affect children under three.

Primary Myelofibrosis - Pipeline Therapeutic Assessment

This section of the report covers the analysis of primary myelofibrosis drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The primary myelofibrosis pipeline analysis report covers 50+ drug analyses based on drug classes:

• Oligonucleotide
• Peptide
• Small molecule

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Primary Myelofibrosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total primary myelofibrosis clinical trials. Phase II leads with 50%, followed by phase I (37%), phase III (10%), dominating the primary myelofibrosis landscape. This distribution highlights a strong concentration of clinical development in early- to mid-stage trials, reflecting ongoing efforts to expand therapeutic options and advance novel targeted treatments for primary myelofibrosis.

Primary Myelofibrosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the primary myelofibrosis pipeline analysis include oligonucleotides, peptides, and small molecules. The primary myelofibrosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for primary myelofibrosis. In September 2023, when the U.S. FDA approved momelotinib (Ojjaara) for adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis with anemia, based on Phase 3 MOMENTUM data demonstrating improvements in symptoms, spleen volume, and anemia outcomes.

Primary Myelofibrosis Clinical Trials - Key Players

The report for the primary myelofibrosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed primary myelofibrosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in primary myelofibrosis clinical trials:

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Bristol-Myers Squibb
• Ryvu Therapeutics SA
• Ajax Therapeutics, Inc.
• Cellenkos, Inc.
• Incyte Corporation
• Hangzhou GluBio Pharmaceutical Co., Ltd.
• Karyopharm Therapeutics Inc
• Geron Corporation
• AbbVie

Primary Myelofibrosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for primary myelofibrosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of primary myelofibrosis drug candidates.

Drug: AJ1-11095

AJ1-11095 is a first-in-class Type II JAK2 inhibitor developed by Ajax Therapeutics, Inc., designed to selectively bind to the inactive conformation of the JAK2 kinase, distinguishing it from existing Type I inhibitors. It targets aberrant JAK2 signaling in primary myelofibrosis, aiming to reduce bone marrow fibrosis and mutant allele burden while potentially overcoming resistance to current JAK inhibitors. Ajax Therapeutics is advancing AJ1-11095 through a Phase 1 clinical trial and has secured orphan drug designation from the FDA, reflecting its novel mechanism and unmet need in myelofibrosis treatment.

Drug: DISC-0974

DISC-0974 is an investigational monoclonal antibody developed by Disc Medicine, Inc. (in-licensed from AbbVie) that targets hemojuvelin (HJV) to suppress hepcidin production, a key regulator of iron homeostasis implicated in anemia seen in myelofibrosis. By lowering hepcidin, DISC-0974 increases iron availability for erythropoiesis, addressing anemia, a significant clinical burden in myelofibrosis patients. Disc Medicine is conducting Phase 1b/2 studies to assess safety, tolerability, and hematologic benefits, positioning the drug as a potential first-in-class anemia-directed therapy within the myelofibrosis landscape.

Drug: INCB057643

INCB057643 is an oral small-molecule BET (bromodomain and extra-terminal) inhibitor developed by Incyte Corporation that modulates epigenetic regulators implicated in proinflammatory and oncogenic pathways relevant to myelofibrosis. By inhibiting BET proteins, it can alter transcription programs linked to cytokine production and malignant cell survival, which may complement JAK inhibitor therapy. Clinical evaluations have included monotherapy and combination studies with JAK inhibitors like ruxolitinib to explore tolerability and potential enhancement of clinical responses in relapsed or refractory myelofibrosis. Incyte continues to include INCB057643 in its early-stage MPN pipeline as part of broader efforts to expand beyond standard JAK-STAT pathway inhibition.

Key Questions Answered in the Primary Myelofibrosis Pipeline Insight Report

• Which companies/institutions are leading the primary myelofibrosis drug development?
• Which company is leading the primary myelofibrosis pipeline development activities?
• What is the current primary myelofibrosis commercial assessment?
• What are the opportunities and challenges present in the primary myelofibrosis pipeline landscape?
• What is the efficacy and safety profile of primary myelofibrosis pipeline drugs?
• Which company is conducting major trials for primary myelofibrosis drugs?
• Which companies/institutions are involved in primary myelofibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in primary myelofibrosis?

Reasons To Buy This Report

The Primary Myelofibrosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for primary myelofibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into primary myelofibrosis collaborations, regulatory environments, and potential growth opportunities.